瑞扎芬净对耳念珠菌的活性
本文为叙述性综述,总结瑞扎芬净对耳念珠菌分离株及感染的活性与有效性证据。体外、体内非临床实验及利用临床数据的药代动力学/药效学靶值达成估算显示,瑞扎芬净活性与其他棘白菌素相当或更优,但对fks突变株活性降低。目前缺乏治疗耳念珠菌感染的数据,作者认为瑞扎芬净可能是治疗耳念珠菌所致念珠菌血症和侵袭性念珠菌病的可行选择,需进一步临床研究。
要点
- 瑞扎芬净对耳念珠菌的体外和体内活性与其他棘白菌素相当或更优。
- 与其他棘白菌素一样,瑞扎芬净对fks突变株的活性降低。
- 作者认为瑞扎芬净可能是治疗耳念珠菌所致念珠菌血症和侵袭性念珠菌病的可行选择。
核心结论
- 尽管目前缺乏瑞扎芬净治疗耳念珠菌感染的数据,作者认为瑞扎芬净可能是治疗耳念珠菌所致念珠菌血症和侵袭性念珠菌病的可行选择,需进一步临床研究。
研究设计与样本
- 叙述性综述,描述瑞扎芬净对耳念珠菌分离株和感染的活性及有效性现有证据。
主要发现
- 瑞扎芬净对耳念珠菌分离株和感染的活性已在体外和体内非临床实验以及利用临床数据的药代动力学/药效学靶值达成估算中得到证实。
- 瑞扎芬净的体外和体内活性与其他棘白菌素相当或更优,并与瑞扎芬净对其他念珠菌属的活性相似。
- 与其他棘白菌素一样,瑞扎芬净对fks突变株的活性降低。
局限性
- 目前缺乏瑞扎芬净治疗耳念珠菌感染的治疗活性数据。
- 需进一步临床研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The increasing prevalence of candidemia and invasive candidiasis infections caused by Candida auris represents a global health risk. Such infections are difficult to treat as they are often multidrug-resistant and are linked to high rates of mortality. Rezafungin is a second-generation echinocandin with antifungal activity against a range of Candida species, including wild type, and azole- and some echinocandin-resistant isolates. Its stability and prolonged half-life permit less frequent dosing compared with other echinocandins, leading to high front-loaded exposures and potential earlier mycological clearance from infection sites. These properties make rezafungin a candidate for the treatment of candidemia and invasive candidiasis infections due to C. auris. Accordingly, this narrative review article describes available evidence for the activity and effectiveness of rezafungin against C. auris isolates and infections. To date, the activity of rezafungin against C. auris isolates and infections has been demonstrated in in vitro and in vivo non-clinical experiments, and in pharmacokinetic/pharmacodynamic target attainment estimations utilizing clinical data. With similar potency to other echinocandins, rezafungin demonstrates in vitro and in vivo activity that is comparable to or better than that seen with other echinocandins, and similar to that for rezafungin in other Candida species. Like other echinocandins, its activity is reduced in fks-mutant isolates. Although there is currently a dearth of data on the therapeutic activity of rezafungin against C. auris, it is reasonable that rezafungin may be a viable choice for treating candidemia and invasive candidiasis caused by C. auris. Further clinical investigations are necessary.
引用
- Locke JB, Andes D, Flanagan S, et al. Activity of rezafungin against Candida auris. J Antimicrob Chemother. 2025. PMID: 40304092. doi:10.1093/jac/dkaf124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。